Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Etsy

Inmode Ltd

Lululemon Athletica

Teladoc

When the market is in the doldrums, it's time to go bargain hunting. Many top growth stocks have suffered in recent times -- and some have what it takes to soar when the general environment improves.

5 Top Growth Stocks to Buy Before the Next Bull Market

Axsome Therapeutics

Axsome is selling two products that could each deliver peak revenue of more than $1 billion. Moderna aims to soon win regulatory approval for a product outside its blockbuster coronavirus vaccine program.

2 Top Biotech Stocks to Buy in April

Johnson & Johnson

J&J is dropping out of the adult RSV vaccine race. This leaves the market to Moderna, Pfizer, and GSK; all three are close to reaching commercialization with their vaccine candidates.

Could This Move by Johnson & Johnson Equal Billions for Moderna?

GlaxoSmithKline

Pfizer

Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out. The post J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out appeared first on Investor's Business Daily.

J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out

Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global public health commitments The facility will be capable of producing up to 500 million doses each year CAMBRIDGE, MA & NAIROBI, KENYA / ACCESSWIRE / March 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an mRNA manufacturing facility in the Republic of Kenya. This will be the Company's first mRNA manufacturing facility in Africa.

Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility

VANCOUVER, British Columbia--(BUSINESS WIRE)--Gandeeva Therapeutics, Inc., a precision medicine company focused on designing and developing novel therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the initiation of a research collaboration with Moderna Inc. (NASDAQ: MRNA) to explore applications of Gandeeva's differentiated technology platform for a Moderna program.

Gandeeva and Moderna Enter into Cryo-EM Research Collaboration to Explore Protein Surface Structure at Atomic Resolution

Demand for the company's COVID-19 vaccine could fall by significantly more than what investors were expecting. Revenue this year could top $5 billion, but in 2024 it may be much lower than that.

Moderna's CEO Just Gave Investors a Huge Reason to Sell the Stock

Moderna brought in blockbuster sales from its coronavirus vaccine, but its major growth isn't over. The company aims to file for approval of its RSV vaccine candidate -- a blockbuster opportunity -- in the first half of this year.

The Ultimate Growth Stock to Buy With $150 Right Now

Apple

Your portfolio needs to have stocks that'll expose it to long-term growth. Moderna's shares are selling on the cheap right now, and its growth runway is long.

2 Nasdaq 100 Stocks to Buy Hand Over Fist Right Now

Moderna's post-pandemic vaccine sales aren't likely to reach the levels we've seen during the height of the pandemic. Now, the company is preparing for its next phase of growth.

3 Things About Moderna That Smart Investors Know

Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.

Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

CAMBRIDGE, MA / ACCESSWIRE / March 24, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 11, 2023.

Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023

CGI Group

Micron Technology

QUALCOMM

Biogen

BioNTech SE

Sociedad Quimica Y Minera De Chile

Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won't do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they're tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts.

7 Blue-Chip Stocks Sitting in the Sweet Spot

Moderna CEO Stéphane Bancel faced sharp criticism at a US Senate hearing Wednesday over the company's plan to quintuple the price of its Covid vaccine when it hits the private market.  Moderna intends to increase the list price of its vaccine to $130 for the private market, compared to the $26 per dose the company has been charging the US government.

Moderna CEO draws Bernie Sanders' ire over plans to raise vaccine price 5x for consumer markets

Generation Bio

Shares of Generation Bio Co. GBIO, -0.51% jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. MRNA, -2.58% to to develop novel nucleic acid therapeutics. Moderna will make an upfront payment of $40 million in cash, in addition to a $36 million equity investment “at a premium over recent share prices.

Generation Bio, Moderna announce collaboration

Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license Generation Bio's ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program Moderna will fund all research and development activities under the collaboration Generation Bio will receive a $40 million upfront cash payment, a pre-payment of research funding, plus a $36 million equity investment from Moderna, with the potential for additional milestones, fees, and royalties CAMBRIDGE, MA / ACCESSWIRE / March 23, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

Moderna's share price has soared over 896% in the last 5 years, compared to just 60% for the S&P 500. That success is built on the company's Covid-19 vaccine.

Moderna Is Great Value For Money Right Now

Moderna CEO Stéphane Bancel tried to defend the company's plan to increase the price of its COVID-19 vaccine during a congressional hearing that raised longstanding questions about how drugs should be priced in the U.S.

Moderna CEO defends price increase for COVID vaccine to Congress

Bernie Sanders pressed Stephane Bancel during the Senate hearing to make a commitment that Moderna will not increase the vaccine's list price to $130.

Moderna CEO Stephane Bancel defends fivefold price hike of Covid vaccine during Senate grilling

"On top of all this, we're expecting a 90% reduction in demand," Bancel said. "As you can see, we're losing economies of scale.

Moderna CEO defends $130 COVID vax price after Bernie Sanders jab

Moderna, Inc. stock's downward spiral from its December highs accelerated, with a staggering 40% collapse toward its March lows. Beyond its COVID vaccine triumph, Moderna must prove its mettle in sustaining operating profitability and growth.

Moderna: Now's Your Chance (Rating Upgrade)

The company is preparing for commercial distribution of the shots as the U.S. winds down its pandemic-emergency purchases.

Moderna to Price Its Covid-19 Vaccine at $130 a Dose

Sen. Bernie Sanders is expected to focus on the company's plans to charge insurers $130 per dose for its Covid-19 vaccine.

Moderna CEO to Face Senate Committee About Covid Vaccine Pricing

Loading up on quality stocks while valuations are low is a good idea. Pfizer's pipeline will be getting a bolt-on expansion with its Seagen acquisition.

2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market

The vaccine's revenue would help Pfizer make up for looming patent cliffs. GSK's annual financials were the healthiest of the three companies.

News for Moderna Stock (MRNA)